When creating groundbreaking health care technology, keeping products user friendly is a necessity. Photo via Getty Images

In the vibrant landscape of startups, the quest to build groundbreaking products can sometimes overshadow the true essence of our existence — to solve problems for our customers.

It's a trap many fall into, often leading to two common outcomes: prolonged product launches stretching over years or an unfortunate mismatch between product and market leading to startup death. But a dynamic solution exists, minimum viable products, or MVPs. MVP has propelled startups to unprecedented success.

A real-life testimony: MVP's power

Imagine a health care-focused at-home testing startup partnered with a major player. The aim: a telehealth support system for the at-home colon cancer screening. Unlike traditional telehealth services, this system required guiding members through a complex process of collecting stool samples accurately.

Challenges presented

  • Develop a user-friendly telehealth solution in five to six weeks on a limited budget and secure a high-stakes multimillion-dollar deal.
  • Carefully integrating telehealth on the existing portal for user-friendly access while aligning seamlessly with user expectations.
  • Address the complexities of Telehealth, including clinician staffing and regulatory adherence.

User Insights

User journeys and interviews confirmed the necessity for guided support during test-taking, but users showed reluctance to navigate the process independently and expressed a preference for customer support over a clinician assistant.

Interestingly, telehealth was not instinctively linked to test support, but rather to medical advice.

The birth of an MVP strategy: a catalyst for innovation

Since the main user problem was the guided support during test-taking, we created the following MVP solutions.

  • Video call integration: Direct video call button under customer support.
  • Guided messaging: Articulate call support purpose.
  • Testing guides: Portal's step-by-step guidance with videos.
  • Video guide in test kit materials.

Our MVP led us to an excellent NPS score and became a guide for our future roadmap.

Next time you build, remember this and embrace the dynamic MVP strategy — create, learn, and reiterate are the cornerstones of success in digital health product management's journey.

Here are four steps for building a successful MVP in telehealth.

  • Identify crucial user problems: Pinpoint your target customers' most pressing issue.
  • Solve a small problem simply: Initiate a straightforward solution to address a minor problem.
  • Plot the user's journey: Map out the user's path through your solution.
  • Prioritize ruthlessly: Discern the key features and prioritize with precision.
------

Tanu Jain is the founder and CEO of Houston-based Digital Health Innovator, a strategic marketing firm for health care products.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."